Jazz Pharmaceuticals PLC logo

Jazz Pharmaceuticals PLC

1
NAS:JAZZ (Ireland)  
$ 117.52 -1.32 (-1.11%) 07:08 PM EST
133.56
P/B:
2.12
Enterprise V:
$ 11.69B
Volume:
928.82K
Avg Vol (2M):
578.50K
Also Trade In:
Volume:
928.82K
Avg Vol (2M):
578.50K

Business Description

Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Name Current Vs Industry Vs History
Cash-To-Debt 0.27
Equity-to-Asset 0.31
Debt-to-Equity 1.66
Debt-to-EBITDA 7.12
Interest Coverage 1.94
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.27
Distress
Grey
Safe
Beneish M-Score -2.77
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 17.19
9-Day RSI 29.25
14-Day RSI 36.54
6-1 Month Momentum % -14.51
12-1 Month Momentum % -15.89

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.06
Quick Ratio 1.67
Cash Ratio 1.01
Days Inventory 498.64
Days Sales Outstanding 59.93
Days Payable 77.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4
Shareholder Yield % 3.3

Financials (Next Earnings Date:2024-05-10 Est.)

JAZZ's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:JAZZ

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Jazz Pharmaceuticals PLC Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3,834.204
EPS (TTM) ($) 6.12
Beta 0.19
Volatility % 20.92
14-Day RSI 36.54
14-Day ATR ($) 3.93454
20-Day SMA ($) 125.158
12-1 Month Momentum % -15.89
52-Week Range ($) 111.2506 - 147.98
Shares Outstanding (Mil) 62.96

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Jazz Pharmaceuticals PLC Filings

Filing Date Document Date Form
No Filing Data

Jazz Pharmaceuticals PLC Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Jazz Pharmaceuticals PLC Frequently Asked Questions

What is Jazz Pharmaceuticals PLC(JAZZ)'s stock price today?
The current price of JAZZ is $117.52. The 52 week high of JAZZ is $147.98 and 52 week low is $111.25.
When is next earnings date of Jazz Pharmaceuticals PLC(JAZZ)?
The next earnings date of Jazz Pharmaceuticals PLC(JAZZ) is 2024-05-10 Est..
Does Jazz Pharmaceuticals PLC(JAZZ) pay dividends? If so, how much?
Jazz Pharmaceuticals PLC(JAZZ) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1